Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vamikibart in Uveitic Macular Edema
NCT05642325Phase 3Completed
- Sponsor
- Roche
- Start
- Mar 2023
- Primary completion
- May 2025
- Modality
- Monoclonal Antibodies
- Countries
- 19
01
Overview
Phase 3, randomised, double-blind trial of vamikibart in uveitic macular edema (UME) (3 arms), sponsored by Roche. Primary endpoint: Proportion of participants with >= 15 letter improvement from baseline in best-corrected visual acuity at 16 weeks. Started Mar 2023; status: completed.
02
Drugs
vamikibart
03
Conditions
uveitic macular edema (UME)
Beyond the preview
Go deeper on NCT05642325.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05642325.